Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland;Koszty przewlekłej obturacyjnej choroby płuc u pacjentów leczonych w ramach specjalistycznej opieki ambulatoryjnej w Polsce

Pneumonologia i Alergologia Polska

Volumn 79, Issue 5, 2011, Pages 337-342

  Jahnz Rózyk, Karina ^a   Targowski, Tomasz ^b   SŁawomir, From ^b   Faluta, Tomasz ^b   Łukasz, Borowiec ^b  

^a Wojskowego Instytutu Medycznego   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Chronic obstructive pulmonary disease; Direst costs; Poland; Social perspective

Indexed keywords

AMBULATORY CARE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; OXYGEN THERAPY; POLAND; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; STATISTICS;

AMBULATORY CARE; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; OXYGEN INHALATION THERAPY; POLAND; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 80052040652     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chapman K.R., Mannino D.M., Soriano J.B. i wsp. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188-207.
2. Halbert R.J., Natoli J.L., Gano A. i wsp. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 523-632.
3. Halpin D.M.G., Miravitlles M. Chronic obstructive pulmonary disease. The disease and its burden to society. Proc. Am. Thorac. Soc. 2006; 3: 619-623.
4. Ramsey S.D., Sullivan S.D. The burden of illness and economic evaluation for COPD. Eur. Respir. J. 2003; 21: 29S-35S.
5. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) http://www.goldcopd.com/
6. Hvidsten S.Ch., Storesund L., Wentzel-Larsen T. i wsp. Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in Norvegian adult general population. Clin. Respir. J. 2010; 4: 13-21.
7. Hilleman D.E., Dewan N., Malesker M. i wsp. Pharmacoeco-nomic evaluation of COPD. Chest 2000; 118: 1278-1285.
8. Pauwels R.A., Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease. Lancet 2004; 364: 613-620.
9. Berger M.L., Bingefors K., Hedblom E.C. Health care cost, quality, and outcomes. ISPOR book of terms. International Society of Pharmacoeconomics and Outcome research. USA, 2003.
10. Drummond M. Cost of illness studies: A major headache? Phar-macoeconomics 1992; 2: 1-4.
11. Rice D.P. Cost of illness studies: fact or fiction. Lancet 1994; 344: 1519-1520.
12. Jahnz-Rózyk K., Targowski T., From S. Koszty leczenia zaos-trzeń POChP w warunkach ambulatoryjnych i szpitalnych w Polsce. Pol. Merk. Lek. 2009; 26: 208-214.
13. Jahnz-Rózyk K., Targowski T., From S. Porównanie kosztów leczenia umiarkowanych i cie{ogonek}żkich zaostrzeń przewlekłej obtu-racyjnej choroby płuc w Polsce w warunkach ambulatoryjnych i szpitalnych. Pneumonol. Alergol. Pol. 2008; 76: 426-431.
14. Efron B., Tibshirani R.J. An introduction to the bootstrap. Chapman & Hall, New York 1993.
15. Wytyczne Prowadzenia Oceny Technologii Medycznych. www.aotm.gov.pl
16. Pierzchała W., Barczyk A., Górecka D. i wsp. Recommendations of Polish Society of Lung Diseases about diagnosis and therapy of chronic obstructive pulmonary disease. Pneumonol. Alergol. Pol. 2010; 78: 318-347.
17. Wouters E.F. Economic analysis of the confronting COPD survey: an overview of results. Respir. Med. 2003; 97 (supl. C): S3-S14.
18. Soto F.J., Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr. Op. Pulm. Med. 2003; 9: 117-124.
19. Wedzicha J., Calverley P., Seemungal T.A. i wsp. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26.
20. Wedzicha J.A., Donaldson G.C. Exacerbations of chronic obstructive pulmonary disease. Respir. Care 2003; 48: 1204-1213.
21. Jassem E., Kozielski J., Górecka D. i wsp. Integrated care for patients with advanced chronic obstructive pulmonary disease. Pneumonol. Alergol. Pol. 2010; 78: 126-132.
22. th annual international meeting. May 15-19, 2010, Atlanta, GA.
23. Bak-Drabik K., Ziora D. Jakość życia w przewlekłej obturacyjnej chorobie płuc. Pneumonol. Alergol. Pol. 2004; 72: 128-133.
24. Fayers P.M., Machin D. Quality of Life. JohnWiley & Sons, England 2007.
25. Grabowska-Krawiec P. Wpływ aleksytymii, poziomu depresji i psychoedukacji na jakość życia i obraz kliniczny chorych na astme{ogonek} lub przewlekła{ogonek} obturacyjna{ogonek} chorobe{ogonek} płuc. Praca doktors-ka, Wojskowy Instytut Medyczny, Warszawa 2009.
26. Jones P.W., Quirk F.H., Baveystock C.M. i wsp. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-1327.
27. Van Schayck C.P., Dompeling E., Rutten M.P. i wsp. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995; 107: 1199-1205.
28. Antoniu S.A. Adherence to inhaled therapy in COPD: effects on survival and exacerbations. Exp. Rev. Pharm. Outcom. Res. 2010; 10: 115-117.
29. Vestbo J., Anderson J.A., Calverly P.M.A. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 939-943.
30. Van Beest F.P., Van Hek-Sukel M., Lammers J.W. i wsp. Less than 20% of COPD patients persist with long-acting inhaled drugs for three years. ISPOR, Paryż, 2009 (praca przedstawiona w formie plakatu). Value in Health 2009; 12: A299.